-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CuBmnnrPuTYjyLOJePSMN+kMeH5ACHeWNKXNlycB/33jaInN3OBM0R25pZ5wjWeV anFJacRu7ChDZyDE67VskQ== 0000950137-02-001357.txt : 20020415 0000950137-02-001357.hdr.sgml : 20020415 ACCESSION NUMBER: 0000950137-02-001357 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020318 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CIMA LABS INC CENTRAL INDEX KEY: 0000833298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411569769 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24424 FILM NUMBER: 02578169 BUSINESS ADDRESS: STREET 1: 10000 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344-9361 BUSINESS PHONE: 9529478700 MAIL ADDRESS: STREET 1: 10000 VALLEY VIEW ROAD CITY: EDEN PRAIRIE STATE: MN ZIP: 55344-9361 8-K 1 c68163e8-k.txt CURRENT REPORT ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 March 18, 2002 ------------------------------------------------ Date of report (Date of earliest event reported) CIMA LABS INC. ------------------------------------------------------ (Exact Name of Registrant as Specified in its Charter) Delaware 0-24424 41-1569769 ------------------------ ------------------------ ------------------- (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 10000 Valley View Road, Eden Prairie, Minnesota 55344-9361 ------------------------------- ---------- (Address of Principal Executive (Zip Code) Offices) Telephone Number: (952) 947-8700 ---------------------------------------------------- (Registrant's Telephone Number, Including Area Code) ================================================================================ ITEM 5. OTHER EVENTS. On March 18, 2002, CIMA LABS INC. (the "Company") announced that Dr. John M. Siebert, Ph.D., President, Chief Executive Officer and Director of the Company, plans to retire from the Company. Attached as Exhibit 99 is a copy of the press release relating to the planned retirement of Dr. Siebert, which is incorporated herein by reference. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) EXHIBITS. Exhibit Description 99 Press Release dated March 18, 2002. SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 18, 2002 CIMA LABS INC. (Registrant) By /s/ David A. Feste --------------------------------------- David A. Feste Vice President, Chief Financial Officer and Secretary INDEX TO EXHIBITS
EXHIBIT NUMBER DESCRIPTION METHOD OF FILING ------- ----------- ---------------- 99 Press Release dated March 18, 2002. Filed herewith.
EX-99 3 c68163ex99.txt PRESS RELEASE EXHIBIT 99 FOR IMMEDIATE RELEASE JOHN M. SIEBERT ANNOUNCES INTENTION TO RETIRE AS PRESIDENT AND CEO OF CIMA LABS MARCH 18, 2002--EDEN PRAIRIE, MN--CIMA LABS INC. (Nasdaq: CIMA) today announced the decision of John M. Siebert, Ph.D., President and Chief Executive Officer, to retire from the Company on December 31, 2003. CIMA's Board of Directors has appointed a search committee to identify and recruit qualified candidates, both external and internal, for the president and chief executive officer position. To assist in an effective succession, Siebert will become, at the appointment of his successor, the Chairman of CIMA's Board of Directors, replacing Terrence W. Glarner. Siebert commented: "Leading CIMA's transition from a small development-stage company to a successful and profitable enterprise has been the most challenging, the most exciting and the most professionally rewarding period of my career. My decision to retire from my management positions and become board chairman will enable me to focus more of my time and attention to ensuring that CIMA remains as vigorous in the future as it is today. I look forward to completing my service with CIMA by helping implement an effective, orderly transition to new leadership." Glarner said: "John Siebert joined CIMA as a member of its Board of Directors in 1992 and became president and chief executive officer in 1995. CIMA, under Siebert's leadership, has become a recognized leader in the global fast-dissolve drug delivery market with five currently marketed brands and the largest product pipeline in the company's history. As a result, John set the course by which CIMA has become a profitable, growing drug delivery company with a bright future." Glarner continued: "The actions announced today are the culmination of succession planning discussions designed to facilitate a seamless management transition. As a result of this process, continuity of our business operations is assured, enabling CIMA to continue pursuing, without interruption, its growing range of market opportunities." ABOUT CIMA LABS CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(R). Based on our technologies, an active drug ingredient is formulated into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. CIMA's fast-dissolve technologies also incorporate taste masking agents to prevent or minimize the unpleasant taste associated with many active drug ingredients. Our business is currently focused on pharmaceutical company partners for whom we manufacture three branded prescription pharmaceuticals and two over-the-counter brands. In a new strategic initiative, CIMA is internally developing proprietary products based on pharmaceuticals that are expected to lose marketing exclusivity over the next several years. These new proprietary products will utilize our OraSolv and DuraSolv fast-dissolve technologies, as well as our new OraVescent(TM) technology, an enhanced absorption, transmucosal drug delivery system. # # # For information, contact: CIMA LABS INC., Eden Prairie David A. Feste, CFO 952-947-8700 or Equity Market Partners Richard G. Cinquina 212/461-7145 or 612/338-0810 -----END PRIVACY-ENHANCED MESSAGE-----